Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A05588 | 33198092 | Diagnostics (Basel) | Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. | 2020 | Details |
| A05596 | 33195347 | Front Med (Lausanne) | Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases. | 2020 | Details |
| A05597 | 33195340 | Front Med (Lausanne) | Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. | 2020 | Details |
| A05598 | 33195326 | Front Med (Lausanne) | Hypoxia and Non-alcoholic Fatty Liver Disease. | 2020 | Details |
| A05604 | 33193088 | Front Endocrinol (Lausanne) | Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity. | 2020 | Details |
| A05605 | 33191435 | Adv Nutr | Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease? | 2020 | Details |
| A05608 | 33190588 | Autophagy | TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. | 2020 | Details |
| A05611 | 33190008 | Complement Ther Clin Pract | The effects of sumac (Rhus coriaria L.) powder supplementation in patients with non-alcoholic fatty liver disease: A randomized controlled trial. | 2020 | Details |
| A05612 | 33188625 | J Physiol Biochem | Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway. | 2020 | Details |
| A05615 | 33187255 | Cells | Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. | 2020 | Details |
| A05617 | 33186794 | Biomed Pharmacother | Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. | 2020 | Details |
| A05619 | 33186403 | PLoS One | Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. | 2020 | Details |
| A05623 | 33185911 | Hepatology | Neutral Ceramidase Mediates Nonalcoholic Steatohepatitis by Regulating Monounsaturated Fatty Acids and Gut IgA+ B Cells. | 2021 | Details |
| A05624 | 33185364 | N Engl J Med | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A05632 | 33182038 | Int Immunopharmacol | Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-κB and MAPK pathways and activating the Nrf2 pathway in mice. | 2020 | Details |
| A05637 | 33179890 | Am Fam Physician | Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. | 2020 | Details |
| A05639 | 33179077 | Mol Med Rep | In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. | 2020 | Details |
| A05641 | 33178320 | Evid Based Complement Alternat Med | Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway. | 2020 | Details |
| A05645 | 33177546 | Sci Rep | PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. | 2020 | Details |
| A05646 | 33176658 | Curr Diabetes Rev | Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis. | 2021 | Details |
| A05650 | 33173107 | Sci Rep | Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. | 2020 | Details |
| A05660 | 33169705 | Turk J Gastroenterol | Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis? | 2020 | Details |
| A05661 | 33169409 | Hepatology | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. | 2021 | Details |
| A05663 | 33168782 | Aging (Albany NY) | Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. | 2020 | Details |
| A05668 | 33166032 | Phytother Res | Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: A randomized clinical trial. | 2020 | Details |
| A05670 | 33165307 | Panminerva Med | Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis. | 2020 | Details |
| A05675 | 33164304 | Liver Int | Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05677 | 33163832 | Hepatol Commun | Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. | 2020 | Details |
| A05678 | 33163831 | Hepatol Commun | Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis. | 2020 | Details |
| A05683 | 33160101 | Mol Metab | Genetic and epigenetic factors determining NAFLD risk. | 2020 | Details |
| A05687 | 33157318 | Clin Gastroenterol Hepatol | Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. | 2020 | Details |
| A05692 | 33153965 | Surg Obes Relat Dis | Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. | 2020 | Details |
| A05700 | 33150145 | J Hepatocell Carcinoma | Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. | 2020 | Details |
| A05703 | 33149804 | Oxid Med Cell Longev | Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD). | 2020 | Details |
| A05705 | 33148902 | J Med Invest | Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. | 2020 | Details |
| A05706 | 33148171 | BMC Gastroenterol | Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. | 2020 | Details |
| A05707 | 33147705 | Nutrients | Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. | 2020 | Details |
| A05710 | 33145434 | Clin Exp Hepatol | Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A05711 | 33145428 | Clin Exp Hepatol | Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease. | 2020 | Details |
| A05712 | 33145423 | Clin Exp Hepatol | Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. | 2020 | Details |
| A05714 | 33144268 | Ann Anat | Can Dasatinib Ameliorate the Hepatic changes, Induced by Long Term Western Diet, in Mice? | 2020 | Details |
| A05716 | 33144054 | Dig Liver Dis | Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. | 2020 | Details |
| A05717 | 33143903 | Pathology | Electron microscopic observations in perfusion-fixed human non-alcoholic fatty liver disease biopsies. | 2020 | Details |
| A05723 | 33143043 | Biomolecules | Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. | 2020 | Details |
| A05724 | 33142854 | Life (Basel) | Investigation of Genetic Modifiers of Copper Toxicosis in Labrador Retrievers. | 2020 | Details |
| A05725 | 33142714 | J Clin Med | Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis. | 2020 | Details |
| A05726 | 33142400 | Zhonghua Yi Xue Za Zhi | [The evaluation value of transient elastography for liver characteristics in obese children]. | 2020 | Details |
| A05732 | 33140878 | J Gastroenterol Hepatol | Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. | 2021 | Details |
| A05737 | 33138044 | Cancers (Basel) | Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. | 2020 | Details |
| A05738 | 33137488 | Mol Metab | The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice. | 2020 | Details |
| A05741 | 33136250 | J Med Ultrason (2001) | Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2020 | Details |
| A05743 | 33135331 | J Diabetes Investig | Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. | 2020 | Details |
| A05746 | 33134809 | Rheumatol Adv Pract | Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. | 2020 | Details |
| A05751 | 33132645 | World J Gastroenterol | Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. | 2020 | Details |
| A05752 | 33132636 | World J Gastroenterol | Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis? | 2020 | Details |
| A05754 | 33132423 | Nagoya J Med Sci | Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver. | 2020 | Details |
| A05759 | 33131062 | Hepatology | Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. | 2021 | Details |
| A05762 | 33129272 | BMC Gastroenterol | Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT. | 2020 | Details |
| A05765 | 33127832 | Gut | MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. | 2020 | Details |
| A05768 | 33126512 | Int J Environ Res Public Health | Prenatal Exposure to Gutkha, a Globally Relevant Smokeless Tobacco Product, Induces Hepatic Changes in Adult Mice. | 2020 | Details |
| A05769 | 33126411 | Cells | The Role of PPARs in Disease. | 2020 | Details |
| A05771 | 33126224 | Aging (Albany NY) | GDF11 induces mild hepatic fibrosis independent of metabolic health. | 2020 | Details |
| A05772 | 33125745 | Hepatology | Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. | 2021 | Details |
| A05775 | 33125080 | J Clin Endocrinol Metab | Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A05789 | 33116724 | Diabetes Metab Syndr Obes | Association Between Subclinical Left Ventricular Myocardial Systolic Dysfunction Detected by Strain and Strain‑Rate Imaging and Liver Steatosis and Fibrosis Detected by Elastography and Controlled Attenuation Parameter in Patients with Metabolic Syndrome. | 2020 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A05798 | 33114299 | Antioxidants (Basel) | Comparative Effects of Pterostilbene and Its Parent Compound Resveratrol on Oxidative Stress and Inflammation in Steatohepatitis Induced by High-Fat High-Fructose Feeding. | 2020 | Details |
| A05809 | 33111374 | Hepatology | NAFLD: Reporting Histologic Findings in Clinical Practice. | 2021 | Details |
| A05810 | 33110211 | Exp Mol Med | The impact of endotrophin on the progression of chronic liver disease. | 2020 | Details |
| A05812 | 33110165 | Sci Rep | Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. | 2020 | Details |
| A05814 | 33110139 | Sci Rep | Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05816 | 33108854 | Diabetes Metab J | Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05817 | 33108553 | J Med Ultrason (2001) | Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. | 2020 | Details |
| A05821 | 33106137 | Curr Pharm Des | Therapeutic effect of Prdx1 on NAFLD mice may be related to the activation of Nrf-2/HO-1 pathway. | 2020 | Details |
| A05836 | 33102799 | Endocrinol Diabetes Metab | Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. | 2020 | Details |
| A05837 | 33102798 | Endocrinol Diabetes Metab | Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. | 2020 | Details |
| A05838 | 33102797 | Endocrinol Diabetes Metab | Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2020 | Details |
| A05839 | 33102796 | Endocrinol Diabetes Metab | The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. | 2020 | Details |
| A05840 | 33102794 | Endocrinol Diabetes Metab | The metabolic basis of nonalcoholic steatohepatitis. | 2020 | Details |
| A05842 | 33102776 | JGH Open | Timely diagnosis and staging of non-alcoholic fatty liver disease using transient elastography and clinical parameters. | 2020 | Details |
| A05843 | 33102775 | JGH Open | Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. | 2020 | Details |
| A05844 | 33102766 | JGH Open | Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients. | 2020 | Details |
| A05845 | 33102751 | JGH Open | Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. | 2020 | Details |
| A05846 | 33102749 | JGH Open | Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. | 2020 | Details |
| A05848 | 33102399 | Can J Gastroenterol Hepatol | Characteristics of NAFLD Based on Hypopituitarism. | 2020 | Details |
| A05851 | 33101626 | Frontline Gastroenterol | Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. | 2019 | Details |
| A05856 | 33099028 | Ann Hepatol | Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19). | 2020 | Details |
| A05863 | 33096235 | J Nutr Biochem | Nobiletin alleviates high-fat diet-induced nonalcoholic fatty liver disease by modulating AdipoR1 and gp91phox expression in rats. | 2020 | Details |
| A05864 | 33096115 | Life Sci | The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. | 2020 | Details |
| A05866 | 33096076 | Metabolism | Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability. | 2020 | Details |
| A05867 | 33095789 | PLoS One | Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A05868 | 33095528 | Cell Physiol Biochem | Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. | 2020 | Details |
| A05872 | 33093663 | Nat Rev Gastroenterol Hepatol | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. | 2020 | Details |
| A05876 | 33092030 | Int J Mol Sci | Accumulation of 8-hydroxydeoxyguanosine, L-arginine and Glucose Metabolites by Liver Tumor Cells Are the Important Characteristic Features of Metabolic Syndrome and Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. | 2020 | Details |
| A05877 | 33091447 | Life Sci | Significance of MR/OPN/HMGB1 axis in NAFLD-associated hepatic fibrogenesis. | 2020 | Details |
| A05878 | 33091218 | Liver Int | PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. | 2020 | Details |
| A05879 | 33091191 | Hepatol Res | Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works. | 2020 | Details |
| A05882 | 33090099 | Turk J Gastroenterol | Morphological evaluation of the effects of exercise on high-fat-diet-induced liver damage in rats. | 2020 | Details |
| A05885 | 33089412 | J Med Ultrason (2001) | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. | 2020 | Details |
| A05891 | 33086582 | Diagnostics (Basel) | The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. | 2020 | Details |